ARA-290 (cibinetide): what nerve-pain trials found

ARA-290, also called cibinetide, is an experimental peptide derived from erythropoietin research. It was designed to engage a tissue-repair signaling pathway without the red-blood-cell effects of erythropoietin. The clearest human question studied so far is whether it helps small-fiber neuropathy symptoms in people with sarcoidosis or type 2 diabetes. [1–3]

How might it work?

Researchers describe activation of an innate repair receptor associated with responses to tissue injury and inflammation. That proposed pathway is biologically interesting, but the meaningful test is whether a controlled study finds less pain or better nerve function in people. [1]

What did human trials find?

A double-blind pilot enrolled 22 people with sarcoidosis and painful small-fiber neuropathy. Twelve received ARA-290 and ten received placebo for four weeks. Neuropathy symptom scores improved more in the treatment group, but the sample was small and exploratory. [1]

A later blinded sarcoidosis study used daily subcutaneous treatment for 28 days. It reported improved patient-reported symptoms and a rise in measured corneal small-nerve-fiber density versus placebo. This objective finding is encouraging, yet it does not establish durable nerve regeneration throughout the body or benefit in unrelated injuries. [2]

A phase 2 study in people with type 2 diabetes and painful neuropathy also reported symptom improvement and a corneal nerve-density signal in a subgroup. Follow-up was short. These studies justify further clinical testing; they do not make ARA-290 a proven general nerve-healing treatment. [3]

Safety and availability

Small short-term studies found no major treatment-related safety signal, but they are too small to settle uncommon or long-term harms. ARA-290 is investigational. A research vial is not demonstrated to match the product prepared and monitored in the trials. [1–3]